W Gao1, Q Wang2, S Yu3. 1. School of Pharmaceutical Science, Shandong University, 44 Wenhua Xi Road, Jinan, 250012, Shandong, China. 2. Shandong University Affiliated Jinan Central Hospital, 105 Jie Fang Road, Jinan, 250013, Shandong, China. 3. Shandong University Affiliated Jinan Central Hospital, 105 Jie Fang Road, Jinan, 250013, Shandong, China. xingbi3@hotmail.com.
Abstract
BACKGROUND: To assess the efficacy, safety and impact on β-cell function of DPP-4 inhibitors plus metformin in T2DM patients and their difference between Asians and Caucasians. METHODS: We conducted a literature search (from 1 January 2000 to 14 April 2015) for RCTs of DPP-4 inhibitors plus metformin combination therapy in T2DM. RESULTS: A total of 27 RCTs were included. Compared with metformin, DPP-4 inhibitor plus metformin therapy was associated with higher reduction in HbA1c [-0.61 %, -0.69 to -0.52], FPG [-1.10 mmol/l, -1.29 to -0.92], TC [-0.11 mmol/l, -0.20 to -0.02], TG [-0.21 mmol/l, -0.33 to -0.10], HOMA-IR [-0.19, -0.36 to -0.02], gastrointestinal adverse events [OR 0.86, 0.77-0.97] and higher increment in HOMA-β [10.21, 7.73-12.69]. Comparison of HbA1c, FPG, body weight and HOMA-IR changes between Asian and Caucasian patients did not show a significant between-group difference of -0.05 % (-0.30, 0.20; P = 0.69), 0.17 mmol/l (-0.52, 0.85; P = 0.62), -0.15 kg (-0.64, 0.35; P = 0.53) and 0.27 (-0.98, 1.53; P = 0.64) compared with metformin. Comparisons of HOMA-β between Asian and Caucasian patients showed a significant between-group difference of -7.68 (-14.95, -0.42; P = 0.04). CONCLUSION: DPP-4 inhibitors and metformin therapy was effective and safe for T2DM patients. The glucose-lowering efficacy of DPP-4 inhibitors was same in Asian and Caucasian patients, although the effect on HOMA-β was inferior in Asian patients. The effect of DPP-4 inhibitors on HOMA-IR and body weight in Asian patients was comparable with that observed in Caucasian patients.
BACKGROUND: To assess the efficacy, safety and impact on β-cell function of DPP-4 inhibitors plus metformin in T2DM patients and their difference between Asians and Caucasians. METHODS: We conducted a literature search (from 1 January 2000 to 14 April 2015) for RCTs of DPP-4 inhibitors plus metformin combination therapy in T2DM. RESULTS: A total of 27 RCTs were included. Compared with metformin, DPP-4 inhibitor plus metformin therapy was associated with higher reduction in HbA1c [-0.61 %, -0.69 to -0.52], FPG [-1.10 mmol/l, -1.29 to -0.92], TC [-0.11 mmol/l, -0.20 to -0.02], TG [-0.21 mmol/l, -0.33 to -0.10], HOMA-IR [-0.19, -0.36 to -0.02], gastrointestinal adverse events [OR 0.86, 0.77-0.97] and higher increment in HOMA-β [10.21, 7.73-12.69]. Comparison of HbA1c, FPG, body weight and HOMA-IR changes between Asian and Caucasian patients did not show a significant between-group difference of -0.05 % (-0.30, 0.20; P = 0.69), 0.17 mmol/l (-0.52, 0.85; P = 0.62), -0.15 kg (-0.64, 0.35; P = 0.53) and 0.27 (-0.98, 1.53; P = 0.64) compared with metformin. Comparisons of HOMA-β between Asian and Caucasian patients showed a significant between-group difference of -7.68 (-14.95, -0.42; P = 0.04). CONCLUSION:DPP-4 inhibitors and metformin therapy was effective and safe for T2DM patients. The glucose-lowering efficacy of DPP-4 inhibitors was same in Asian and Caucasian patients, although the effect on HOMA-β was inferior in Asian patients. The effect of DPP-4 inhibitors on HOMA-IR and body weight in Asian patients was comparable with that observed in Caucasian patients.
Authors: Juliana C N Chan; Vasanti Malik; Weiping Jia; Takashi Kadowaki; Chittaranjan S Yajnik; Kun-Ho Yoon; Frank B Hu Journal: JAMA Date: 2009-05-27 Impact factor: 56.272
Authors: Michel P Hermans; Tuncay Delibasi; Ian Farmer; Leif Lohm; Pierre Maheux; PierMarco Piatti; Elmas Malvolti; Silke Jörgens; Bernard Charbonnel Journal: Curr Med Res Opin Date: 2012-10-12 Impact factor: 2.580
Authors: Tomoaki Shimizu; David M Nathan; John B Buse; Mayer B Davidson; Ele Ferrannini; Rury R Holman; Robert Sherwin; Bernard Zinman Journal: Nihon Rinsho Date: 2012-05
Authors: F J Lavalle-González; A Januszewicz; J Davidson; C Tong; R Qiu; W Canovatchel; G Meininger Journal: Diabetologia Date: 2013-09-13 Impact factor: 10.122